IP Library Granted Patent US 8,048,918
Granted Patent B2
US 8,048,918 · App. 10/085,239 · Granted Nov 1, 2011

Treatment of hyperproliferative diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,048,918
App. No.
10/085,239
Granted
Nov 1, 2011
Kind
B2
Abstract

We describe methods and compositions for treating a patient suffering from a hyperproliferative disorder or photoageing. Our methods involve blocking the activity of a retinol binding protein receptor (RBPr) in cells of the patient, and/or administering to the patient an antagonist of a retinol binding protein receptor (RBPr) and/or lowering the endogenous level of retinoic acid (RA) in cells of said patient.

Claims (8)

1. A method of treating a hyperproliferative disease of the skin consisting of administering to a patient in need of treatment for a hyperproliferative disease of the skin a pharmaceutical composition consisting of carbenoxolone and one or more pharmaceutically acceptable excipients, wherein the hyperproliferative disease of the skin is selected from the group consisting of psoriasis, acne vulgaris, actinic keratosis, solar keratosis, squamous carcinoma in situ, ichthyoses, hyperkeratosis and Darier's disease.

2. The method of claim 1 , wherein said hyperproliferative disease of the skin is selected from the group consisting of psoriasis, acne vulgaris, and hyperkeratosis.

3. The method of claim 1 , wherein said hyperproliferative disease of the skin is psoriasis.

4. The method of claim 1 , wherein the hyperproliferative disease of the skin is Darier's disease.

5. The method of claim 1 , wherein the pharmaceutical composition is administered topically to an affected area of the skin of the patient in need of treatment for a hyperproliferative disease of the skin.

6. The method of claim 5 , wherein the hyperproliferative disease of the skin is selected from the group consisting of psoriasis, acne vulgaris, and hyperkeratosis.

7. The method of claim 5 , wherein the hyperproliferative disease of the skin is psoriasis.

8. The method of claim 5 , wherein the hyperproliferative disease of the skin is Darier's disease.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2009
From: YORK PHARMA (R&D) LIMITED; ROSANTO PHARMACEUTICALS LIMITED
To: RH ACQUISITIONS LIMITED
Reel/Frame 023694/0945 →
CHANGE OF NAME Recorded Dec 23, 2009
From: RH ACQUISITIONS LIMITED
To: CRAWFORD HEALTHCARE HOLDINGS LIMITED
Reel/Frame 023701/0306 →